Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Chlorotoxin-conjugated graphene oxide for targeted delivery of an anticancer drug

Authors Wang H, Gu W, Xiao N, Ye L, Xu Q

Received 5 December 2013

Accepted for publication 7 February 2014

Published 18 March 2014 Volume 2014:9(1) Pages 1433—1442


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Hao Wang,1 Wei Gu,2 Ning Xiao,2 Ling Ye,2 Qunyuan Xu1

1Regeneration and Repair, Key Laboratory for Neurodegenerative Disease of The Ministry of Education, 2School of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China

Abstract: Current chemotherapy for glioma is rarely satisfactory due to low therapeutic efficiency and systemic side effects. We have developed a glioma-targeted drug delivery system based on graphene oxide. Targeted peptide chlorotoxin-conjugated graphene oxide (CTX-GO) sheets were successfully synthesized and characterized. Doxorubicin was loaded onto CTX-GO (CTX-GO/DOX) with high efficiency (570 mg doxorubicin per gram CTX-GO) via noncovalent interactions. Doxorubicin release was pH-dependent and showed sustained-release properties. Cytotoxicity experiments demonstrated that CTX-GO/DOX mediated the highest rate of death of glioma cells compared with free doxorubicin or graphene oxide loaded with doxorubicin only. Further, conjugation with chlorotoxin enhanced accumulation of doxorubicin within glioma cells. These findings indicate that CTX-GO is a promising platform for drug delivery and provide a rationale for developing a glioma-specific drug delivery system.

Keywords: glioma, nanosheet, pH-dependent, cytotoxicity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]